Here are the 10-Q quarterly reports from Aptose Biosciences, Inc. (APTO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow APTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APTO filings page.
Aptose Biosciences reported a six-month net loss of $12.6 million and held $1.298 million of cash, cash equivalents and restricted cash as of June 30, 2025. Total liabilities were $19.962 million and the company reported negative shareholders' equity of $14.4 million and an accumulated deficit of $553.6 million, with current liabilities exceeding current assets by $5.7 million. Management explicitly states substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing.
On the clinical front, the company is advancing tuspetinib in a Phase 1/2 TUSCANY trial. Ten newly diagnosed AML patients were dosed across 40 mg, 80 mg and 120 mg cohorts with complete remissions (CRs) and MRD-negativity reported at the 40 mg cohort and composite CRs reported at 80 mg and 120 mg; no dose-limiting toxicities were observed and escalation to 160 mg was announced. The company paused further development spending on luxeptinib to prioritize tuspetinib. Related-party financing with Hanmi includes a $10.0 million loan, a debt conversion of $1.538 million into 409,063 shares, and a facility up to $8.5 million with $5.6 million of advances disclosed as subsequent events.